Vaxart’s oral Covid-19 vaccine trial receives BARDA funding

Vaxart has announced a funding boost for its oral Covid-19 vaccine candidate, with the US Biomedical Advanced Research and Development Authority (BARDA) awarding the company $9.27m.

This funding is earmarked for launching a Phase IIb clinical trial of the oral pill vaccine candidate, which is set to involve around 10,000 subjects.